Global Ovulation Inducing Drugs Market: Industry Analysis and Forecast (2020-2026) By Drug Class, Distribution Channel and Region

Global Ovulation Inducing Drugs Market size is expected to reach US$ 5.11 Bn. by year 2026 at a CAGR of 5.8% during the forecast period.

Global Ovulation Inducing Drugs Market Overview:

Anovulation is an infertility condition in which follicles in a woman's ovary do not mature and release eggs for which ovulation treatment is given. Ovulation induction is a treatment for this condition (ovulate). A number of drugs that stimulate the ovary to develop and release eggs are used to induce ovulation.

Global Ovulation Inducing Drugs Market Dynamics:

Rise in prevalence of infertility in women due to various disorders is the primary factor which boosts the market growth. The increasing rates of infertility around the world are driving the growth of the ovulation-inducing drugs market. Infertility is described as the inability to conceive after 12 months of trying. The National Survey of Family Growth (NSFG) in the United States in 2018 stated that 15.5 % of all women planning to become pregnant were infertile, and 6.7 % of married women aged 15 to 44 were infertile. Increased age, polycystic ovarian syndrome (PCOS), obesity, and multiple miscarriages all contribute to female infertility. Obesity, stress, smoking, diabetes, Poly Cystic Ovarian Syndrome (PCOS), and other lifestyle disorders and unhealthy diets are on the rise, resulting in increased demand for ovulation-inducing drugs. According to a study published by the United States Department of Health and Human Services (HHS), PCOS is a global health issue that affects one in every ten women of childbearing age across the world in 2019. As a result, increasing gynecological disorders, which lead to lower fertility rates, are expected to fuel the global market. The side effects of infertility drugs, such as headache, nausea, upper respiratory tract infection, abdominal tenderness, sinus inflammation, mood swings, acne, breast tenderness, weight gain, pelvic discomfort, unexplained bleeding or spotting, vomiting, injection site pain, redness, dizziness, and Ovarian Hyper-Stimulation Syndrome, are limiting the market growth of ovulation-inducing drugs. The report has profiled sixteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.

Global Ovulation Inducing Drugs Market Segment Analysis:

The global Ovulation Inducing Drugs market is segmented on the basis of Drug Class and Distribution Channel. Based on Drug Class, the therapeutic drugs segment is expected to hold a dominant market share during the forecast period. The segment is divided into clomiphene and gonadotropins. Clomiphene or Clomid tablets are the most widely used medications. Clomiphene or Clomid tablets (alternatives include Tamoxifen and Letrozole tablets) stimulate follicles and therefore egg development by increasing the pituitary gland's production of follicle-stimulating hormone (FSH). Clomiphene citrate is a widely used medication that is inexpensive, effective when taken orally, has fewer side effects, and is relatively safe for the foetus. It may be used to treat PCOS-related ovulatory infertility. Global Ovulation Inducing Drugs Market To know about the Research Methodology :- Request Free Sample Report

Global Ovulation Inducing Drugs Market Regional Insights:

  Global Ovulation Inducing Drugs Market Regional Insights North America is expected to dominate the global market during forecast period. During the forecast period, North America is projected to dominate the global ovulation-inducing drugs market. This dominance is primarily due to increasing rates of menopausal disorders, urinary infections, thyroid problems, endometriosis, and other conditions among women as a result of busy lifestyles and increased stress. Also, a rising number of new Food and Drug Administration (FDA) drug approvals are expected to propel the market growth over the forecast period. PCOS affects more than 5 a million women of reproductive age, states a study released by the Centers for Disease Control and Prevention in 2019. The report also helps in understanding Global Ovulation Inducing Drugs Market dynamics, structure by analyzing the market segments and project the Global Ovulation Inducing Drugs Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Ovulation Inducing Drugs Market make the report investor’s guide.

Global Ovulation Inducing Drugs Market, Key Developments:

Ferring Pharmaceuticals, a biopharmaceutical corporation headquartered in the United States, purchased the commercialization rights of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd in 2019 for an undisclosed amount. Ferring Pharmaceuticals hopes to expand its portfolio of reproduction-related medicines as a result of the acquisition. The FDA approved Ganirelix Acetate Injection in 2018 for regulating premature luteinizing hormone (LH) levels in women undergoing fertility treatment.

Global Ovulation Inducing Drugs Market Scope: Inquire before buying

Global Ovulation Inducing Drugs Market

Global Ovulation Inducing Drugs Market, By Region:

• North America • Europe • South America • MEA • APAC

Global Ovulation Inducing Drugs Market, Key players:

• Sanofi • EMD Serono, Inc. • Ferring Pharmaceuticals, Inc. • Fresenius Kabi AG • Merck & Co., Inc. • Sun Pharmaceuticals Industries Ltd. • Serum Institute of India Ltd. • Glenmark Pharmaceuticals Ltd. • LIVZON Pharmaceutical Group Inc. • Abbott Laboratories • Bayer AG • Zydus Pharmaceuticals • Janssen Pharmaceutical Inc. • Pfizer • Novartis AG • Procter & Gamble Pharmaceutical
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Ovulation Inducing Drugs Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Ovulation Inducing Drugs Market 3.4. Geographical Snapshot of the Ovulation Inducing Drugs Market, By Manufacturer share 4. Global Ovulation Inducing Drugs Market Overview, 2019-2026 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Ovulation Inducing Drugs Market 5. Supply Side and Demand Side Indicators 6. Global Ovulation Inducing Drugs Market Analysis and Forecast, 2019-2026 6.1. Global Ovulation Inducing Drugs Market Size & Y-o-Y Growth Analysis. 7. Global Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 7.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 7.1.1. Hormones 7.1.1.1. Follicle stimulating hormone (FSH) 7.1.1.2. Human menopausal gonadotropin (hMG) 7.1.1.3. Human chorionic gonadotropin (hCG) 7.1.2. Therapeutics Drugs 7.1.2.1. Clomiphene or Clomid tablets 7.1.2.2. Gonadotropins 7.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 7.2.1. Hospital pharmacies 7.2.2. Independent pharmacies 7.2.3. Online pharmacies 8. Global Ovulation Inducing Drugs Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2019-2026 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 9.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 9.1.1. Hormones 9.1.1.1. Follicle stimulating hormone (FSH) 9.1.1.2. Human menopausal gonadotropin (hMG) 9.1.1.3. Human chorionic gonadotropin (hCG) 9.1.2. Therapeutics Drugs 9.1.2.1. Clomiphene or Clomid tablets 9.1.2.2. Gonadotropins 9.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 9.2.1. Hospital pharmacies 9.2.2. Independent pharmacies 9.2.3. Online pharmacies 10. North America Ovulation Inducing Drugs Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 11.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 11.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 12. Canada Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 12.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 12.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 13. Mexico Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 13.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 13.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 14. Europe Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 14.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 14.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 15. Europe Ovulation Inducing Drugs Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K. Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 16.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 16.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 17. France Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 17.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 17.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 18. Germany Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 18.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 18.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 19. Italy Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 19.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 19.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 20. Spain Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 20.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 20.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 21. Sweden Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 21.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 21.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 22. CIS Countries Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 22.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 22.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 23. Rest of Europe Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 23.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 23.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 24. Asia Pacific Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 24.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 24.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 25. Asia Pacific Ovulation Inducing Drugs Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 26.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 26.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 27. India Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 27.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 27.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 28. Japan Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 28.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 28.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 29. South Korea Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 29.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 29.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 30. Australia Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 30.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 30.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 31. ASEAN Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 31.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 31.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 32. Rest of Asia Pacific Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 32.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 32.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 33. Middle East Africa Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 33.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 33.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 34. Middle East Africa Ovulation Inducing Drugs Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 35.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 35.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 36. GCC Countries Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 36.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 36.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 37. Egypt Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 37.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 37.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 38. Nigeria Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 38.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 38.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 39. Rest of ME&A Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 39.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 39.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 40. South America Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 40.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 40.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 41. South America Ovulation Inducing Drugs Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 42.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 42.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 43. Argentina Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 43.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 43.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 44. Rest of South America Ovulation Inducing Drugs Market Analysis and Forecasts, 2019-2026 44.1. Market Size (Value) Estimates & Forecast By Drug Class, 2019-2026 44.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Ovulation Inducing Drugs Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Applications and R&D Investment 45.2.2. New Product Launches and Product Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. Sanofi 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Product Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. EMD Serono, Inc. 45.3.3. Ferring Pharmaceuticals, Inc. 45.3.4. Fresenius Kabi AG 45.3.5. Merck & Co., Inc. 45.3.6. Sun Pharmaceuticals Industries Ltd. 45.3.7. Serum Institute of India Ltd. 45.3.8. Glenmark Pharmaceuticals Ltd. 45.3.9. LIVZON Pharmaceutical Group Inc. 45.3.10. Abbott Laboratories 45.3.11. Bayer AG 45.3.12. Zydus Pharmaceuticals 45.3.13. Janssen Pharmaceutical Inc. 45.3.14. Pfizer 45.3.15. Novartis AG 45.3.16. Procter & Gamble Pharmaceutical 46. Primary Key Insights
  • INQUIRE BEFORE BUYING